• The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study

  The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study

  Evidence, MammaPrint, Other, Validation

The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study

PUBLICATION: Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub Read More

kevin2024-03-25T11:09:15-04:00July 27th, 2009|Evidence, MammaPrint, Other, Validation|

Read More

• Daily Clinical Practice of Fresh Tumour Tissue Freezing and Gene Expression Profiling; Logistics Pilot Study Preceding the MINDACT Trial

  Daily Clinical Practice of Fresh Tumour Tissue Freezing and Gene Expression Profiling; Logistics Pilot Study Preceding the MINDACT Trial

  Evidence, MammaPrint, Other

Daily Clinical Practice of Fresh Tumour Tissue Freezing and Gene Expression Profiling; Logistics Pilot Study Preceding the MINDACT Trial

PUBLICATION: Eur J Cancer. 2009 May;45(7):1201-1208. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Read More

kevin2024-03-25T11:09:51-04:00May 1st, 2009|Evidence, MammaPrint, Other|

Read More

• 

  Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics

  Gallery

  Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics

  Evidence, MammaPrint, Other

Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics

PUBLICATION: Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: Read More

kevin2024-03-25T11:11:06-04:00January 24th, 2009|Evidence, MammaPrint, Other|

Read More

• Clinical Application of the 70-gene Profile: The MINDACT Trial

  Clinical Application of the 70-gene Profile: The MINDACT Trial

  Adjuvant, Evidence, MammaPrint, MINDACT

Clinical Application of the 70-gene Profile: The MINDACT Trial

PUBLICATION: J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222. AUTHORS: Read More

kevin2024-03-07T10:56:53-05:00February 11th, 2008|Adjuvant, Evidence, MammaPrint, MINDACT|

Read More

• Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort.

  Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort.

  Adjuvant, Evidence, MammaPrint

Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort.

PUBLICATION: Clin Cancer Res. 2008 May 15;14(10):2988-93. doi: 10.1158/1078-0432.CCR-07-4723. AUTHORS: Read More

kevin2024-03-25T11:14:22-04:00February 10th, 2008|Adjuvant, Evidence, MammaPrint|

Read More

• Use of 70-gene Signature to Predict Prognosis of Patients with Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER)

  Use of 70-gene Signature to Predict Prognosis of Patients with Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER)

  Adjuvant, Evidence, MammaPrint, RASTER

Use of 70-gene Signature to Predict Prognosis of Patients with Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER)

PUBLICATION:  Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov Read More

kevin2024-03-07T10:58:08-05:00December 8th, 2007|Adjuvant, Evidence, MammaPrint, RASTER|

Read More

• Robust Interlaboratory Reproducibility of a Gene Expression Signature Measurement Consistent with the Needs of a New Generation of Diagnostic Tools

  Robust Interlaboratory Reproducibility of a Gene Expression Signature Measurement Consistent with the Needs of a New Generation of Diagnostic Tools

  Evidence, MammaPrint, Other, Validation

Robust Interlaboratory Reproducibility of a Gene Expression Signature Measurement Consistent with the Needs of a New Generation of Diagnostic Tools

PUBLICATION: BMC Genomics. 2007 Jun 7;8:148. AUTHORS: Ach R.A., Floore Read More

kevin2024-03-25T11:15:05-04:00June 7th, 2007|Evidence, MammaPrint, Other, Validation|

Read More

• Individualization of Therapy Using MammaPrint: from Development to the MINDACT Trial

  Individualization of Therapy Using MammaPrint: from Development to the MINDACT Trial

  Adjuvant, Evidence, MammaPrint, MINDACT

Individualization of Therapy Using MammaPrint: from Development to the MINDACT Trial

PUBLICATION: Cancer Genomics & Proteomics. 2007 May-Jun;4(3):147-55. AUTHORS: Mook S., Read More

kevin2024-03-25T11:15:40-04:00May 1st, 2007|Adjuvant, Evidence, MammaPrint, MINDACT|

Read More

• 

  Converting a Breast Cancer Microarray Signature into a High-Throughput Diagnostic Test

  Gallery

  Converting a Breast Cancer Microarray Signature into a High-Throughput Diagnostic Test

  Evidence, MammaPrint, Other, Validation

Converting a Breast Cancer Microarray Signature into a High-Throughput Diagnostic Test

PUBLICATION: BMC Genomics. 2006 Oct 30;7:278. AUTHORS:  Glas A.M., Floore Read More

kevin2024-03-25T11:16:18-04:00October 30th, 2006|Evidence, MammaPrint, Other, Validation|

Read More

• Gene Expression Profiles of Primary Breast Carcinomas from Patients at High-Risk for Local Recurrence After Breast-Conserving Therapy

  Gene Expression Profiles of Primary Breast Carcinomas from Patients at High-Risk for Local Recurrence After Breast-Conserving Therapy

  Evidence, MammaPrint, Other

Gene Expression Profiles of Primary Breast Carcinomas from Patients at High-Risk for Local Recurrence After Breast-Conserving Therapy

PUBLICATION: Clin Cancer Res. 2006 Oct 1;12(19):5705-12. AUTHORS: Kreike B., Read More

kevin2024-03-25T11:17:36-04:00October 1st, 2006|Evidence, MammaPrint, Other|

Read More